CA 125 (ovarian cancer)
CA 125 is a tumour marker associated mainly with ovarian cancer. Together with ultrasound, it is used to assess changes in the ovaries, and to monitor the course of ovarian cancer and the effectiveness of cancer treatment.
Preparation and sampling
- Preparation
- Guide to preparing for tests
- Sample
- Blood
- Results available in
- 1 working day
- Where it is done
- All laboratories and map
Description
About the test
CA 125 (cancer antigen 125) is a glycoprotein produced in small amounts by the cells lining the abdominal and chest cavities and the sac around the heart, and by tissues of the female reproductive organs (the lining of the womb, the fallopian tubes). Healthy people have low levels in their blood.
Many epithelial ovarian cancers – the most common type of ovarian cancer (about 90% of cases) – release large amounts of CA 125 into the blood. The marker is raised in most women with advanced epithelial ovarian cancer, but in only about half of women whose disease is at an early stage.
CA 125 is used mainly to monitor ovarian cancer: to establish a baseline value before treatment, assess the response to treatment and detect recurrence. It is also used to assess an ovarian mass found on ultrasound, together with imaging and other markers (e.g. HE4 as part of the ROMA score).
CA 125 is not a screening test for ovarian cancer in women without symptoms: it can be raised in many non-cancerous conditions, and it is normal in some women with early cancer. After the menopause a raised value carries more weight, because there are fewer benign causes of a rise.
When it is recommended
- assessing an ovarian or pelvic mass found on ultrasound, together with imaging, as recommended by the doctor;
- establishing a baseline value before treatment of ovarian cancer;
- monitoring the response to surgery and chemotherapy;
- follow-up after treatment, to detect recurrence;
- in women at high inherited risk (e.g. carriers of BRCA1/BRCA2 gene mutations), as part of surveillance together with ultrasound, if recommended by a specialist.
Preparation
- Fasting is not necessary for the CA 125 test itself. If you are having other blood tests on the same day, follow the general rule: blood is taken in the morning, between 7 and 10 a.m., after 12 hours of fasting, and you may drink water as usual.
- In women of reproductive age, it is better not to have the test during a period, as CA 125 can be temporarily raised at that time.
- Tell your doctor about pregnancy, endometriosis, fibroids, recent abdominal or pelvic operations or procedures, and whether you have gone through the menopause.
- If the test is for monitoring, tell your doctor your diagnosis and when you had surgery or chemotherapy; tests are done at the intervals the doctor recommends, ideally by the same method and in the same laboratory.
- If you take biotin (vitamin B7, common in hair and nail supplements), tell the laboratory: in high doses it can change the results of some immunoassays. With high doses a break is needed, usually 2–3 days.
Sample
Venous blood.
Reference values
For orientation, the most commonly used upper limit is 35 U/mL.
Values obtained by different methods cannot always be compared directly.
Reference values depend on the method and the laboratory; the values printed on your report apply to your result.
Interpreting the results
High values may be seen in:
- ovarian cancer (especially epithelial), fallopian tube cancer and primary peritoneal cancer;
- cancer of the lining of the womb (endometrial cancer);
- less often, other cancers (pancreas, lung, breast, digestive tract);
- non-cancerous conditions: menstruation, pregnancy (especially the first trimester), endometriosis, fibroids, pelvic inflammatory disease, benign ovarian cysts, liver disease (cirrhosis), pancreatitis, fluid in the abdomen or chest, heart failure, and after abdominal surgery.
A single raised value does not by itself mean cancer, especially in women who have not yet reached the menopause.
In women with known ovarian cancer, a fall after treatment indicates a good response, while a rise on successive measurements may indicate recurrence or progression, which is confirmed by imaging and other investigations.
A value within the reference range does not rule out ovarian cancer: at an early stage the marker is often not raised, and some tumour types (e.g. mucinous tumours) produce little CA 125.
Your doctor interprets the result together with your symptoms and other findings.
What can affect the result
- menstruation and pregnancy;
- endometriosis, fibroids and pelvic inflammation;
- liver disease and fluid in the abdomen or chest;
- recent abdominal operations or procedures;
- differences between the methods and reagents used by laboratories;
- high doses of biotin, depending on the method;
- heterophile antibodies and other interference with immunoassays.
Related tests
- HE4 and the ROMA score (CA 125 + HE4) – to estimate the risk that an ovarian mass is malignant;
- Transvaginal ultrasound, MRI or CT – as recommended by the doctor;
- CA 19-9 and CEA – in some ovarian tumours (e.g. mucinous) and to help distinguish tumours of other organs;
- AFP, β-hCG and LDH – when a germ cell tumour is suspected, especially in younger women;
- Genetic testing (e.g. BRCA1/BRCA2) and genetic counselling – depending on personal and family history.
Frequently ordered together
How to order tests online?
Choose the tests you need and add them to your cart. Use the site search to find the tests you want more easily.
Payment method:
- Online – payment uses 3D-Secure, a secure authentication protocol that minimises the risk of fraud.
- At the laboratory – order your tests online and pay for them when you come to the laboratory.
After payment, you will receive an email confirming your order, with details of how to prepare for sampling. From then on, you can go to the Sante laboratory you chose when ordering your tests and have your samples taken.